Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234507 · ClinicalTrials.gov registry record · Phase 2
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
A Phase 2 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00234507 is a Phase 2 study that has completed, run by Ipsen. The registered enrollment target is 120 participants.
The verdict
NCT00234507, a Phase 2 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
Interventions
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234507
The ClinicalTrials.gov registry entry for NCT00234507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.
NCT00234507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234507 about?
NCT00234507 is a clinical study titled "Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm". The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
What is the current status of trial NCT00234507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2003-01. Estimated completion is 2004-05-25.
What interventions are being tested in trial NCT00234507?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00234507?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.